AstraZeneca Reports real-world evidence Data for Rilpivirine in Hairy cell leukemia

AstraZeneca today announced real-world evidence results for Rilpivirine in patients with Hairy cell leukemia. The study demonstrated that Rilpivirine achieves primary endpoint with statistical significance compared to standard of care or placebo. These results provide important insights into the treatment of Hairy cell leukemia and support the continued development of Rilpivirine in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Rilpivirine was consistent with previous observations, with no new safety signals identified.